Ultragenyx Pharmaceutical Inc
(LTS:0LIF)
$
42.06
-1.5093 (-3.46%)
Market Cap: 3.88 Bil
Enterprise Value: 3.30 Bil
PE Ratio: 0
PB Ratio: 11.20
GF Score: 79/100 Ultragenyx Pharmaceutical Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript
Oct 28, 2021 / 07:30PM GMT
Release Date Price:
$80.65
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Emil Kakkis, the CEO of Ultragenyx.
Thanks for joining us today, Emil.
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director
And thanks for having me, Maury.
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat format. But if anyone in the audience has questions, feel free to submit them online, and we'll try to incorporate them as we go.
But maybe to start off, Emil, if you want to give a brief intro to Ultragenyx, your commercial products and your pipeline.
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director
Sure, Maury. We're 11 years in as a company, and we have 4 approvals of 3 products: a monoclonal antibody for -- called
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot